-
Davis and colleagues report the results of a one-year, randomized, controlled clinical trial of 814 women not on estrogen therapy from 65 centers in the United States, Canada, Australia, the United Kingdom, and Sweden with hypoactive sexual desire disorder treated with transdermal testosterone, 150 or 300 µg per day, or placebo.
-
The authors present a series of gynecological conditions that are effectively diagnosed by hysteroscopy, including adenomyosis, chronic endometritis, Mullerian anomalies, retained fetal bones, endocervical ossification, and intrauterine abnormalities. In addition, they note that hysteroscopy can be a major part of the treatment for these conditions.
-
The adverse publicity following publications from the Women's Health Initiative was a multibillion dollar bonanza for compounding pharmacies providing postmenopausal hormones.
-
-
In this issue: The JUPITER trial causes a stir; ACP practice guideline for antidepressant use; testosterone for low libido; continued shortage of Hib vaccine; FDA Actions.
-
-
Inhaled salmeterol and fluticasone, singly or in combination, reduce the rate of decline of the FEV1 in patients with moderate-to-severe COPD.
-
CT colonographic screening of asymptomatic adults identified 90% of polyps or cancers measuring 10 mm or more.
-
Homocysteine (HCYS) has all the trappings of a first-rate cardiovascular risk factor: as strong an association with CVD endpoints as cholesterol, ease of identification, and simplicity of modulation. Trouble is, trials to date have been unable to show that reductions of homocysteine provide meaningful benefits to patients.
-
Intensive hemoglobin A1c lowering does not reduce the rate of cardiovascular death, and results in an increase in hypoglycemic events.
